Cancer Research UK, Cambridge Research Institute, The Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
Anticancer Res. 2010 Sep;30(9):3223-32.
In this review, we focus on the discrepant roles of the DNA repair complex ERCC1/XPF in the prevention of cancer and in the resistance of cancer to chemotherapy. ERCC1/XPF is essential for nucleotide excision repair (NER) incising DNA 5' to the lesion. NER deficiency results in the skin cancer-prone inherited disease xeroderma pigmentosum (XP). The ERCC1/XPF complex is also involved in recombination, double strand break (DSB) and interstrand crosslink (ICL) repair cutting DNA overhangs around a lesion. In telomere maintenance ERCC1/XPF degrades 3' G-rich overhangs. In some types of cancer, high levels of ERCC1/XPF mRNA and protein correlate with poor overall survival and resistance to platinum-based chemotherapeutic treatments. Therefore, the ERCC1/XPF complex makes an attractive target for prediction of outcome for treatment in cancer patients as well as a novel drug target.
在这篇综述中,我们重点讨论了 DNA 修复复合物 ERCC1/XPF 在预防癌症和癌症对化疗耐药中的差异作用。ERCC1/XPF 对于核苷酸切除修复(NER)在损伤 5' 端切割 DNA 至关重要。NER 缺陷导致皮肤癌易患的遗传性疾病着色性干皮病(XP)。ERCC1/XPF 复合物还参与重组、双链断裂(DSB)和链间交联(ICL)修复,在损伤周围切割 DNA 突出端。在端粒维持中,ERCC1/XPF 降解 3' G 丰富的突出端。在某些类型的癌症中,高表达的 ERCC1/XPF mRNA 和蛋白与整体生存不良以及对铂类化疗药物治疗的耐药性相关。因此,ERCC1/XPF 复合物作为预测癌症患者治疗结果的有吸引力的靶点以及新的药物靶点。